Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GENNEXT TECHNOLOGIES, INC.
- Proposal award date
- 2020-02-01
- Contract end date
- 2023-01-31
- UEI
- KCSNGXRKL276
- Solicitation number
- PA18-574
- Topic code
- 300
Research abstract
The GenNext Phase II SBIR submssion entitled “FoxWare™, an Advanced Data
Analysis Package for Hydroxyl Radical Foot-printing Higher Order Structural Analysis” is
responsive to the ackowledged need for new and improved tools for higher order
structural analysis (HOS) of biopharmaceuticals. Biopharmaceuticals are complex,
heterogeneous mixtures of 3-dimensional biomolecules, whose safety and efficacy is
reliant upon proper HOS. The presence of proteins with improper HOS has been linked
to severe adverse drug reactions (ADR), establishing the need for new and improved
HOS analytics.An emerging HOS analysis technique is hydroxyl radical foot-printing (HRPF).
HRPF involves the irreversible labeling of a protein's exterior by reaction with hydroxyl
radicals with subsequent MS analysis to identify the outer portions of the protein. The
most widely used method for generating OH radicals employs a quick burst of UV light,
and is appropriately called fast photochemical oxidation of proteins (FPOP). Academic
laboratories have demonstrated the utility of FPOP for HOS analysis; however adoption
in pharma has been minuscule at best. Guided by the critiques of scientists at leading
biopharmaceutical companies, we have identified barriers that have limited pharma's
adoption of FPOP HRPF. A substantial barrier is the absence of data processing
tools to facilitate HRPF analysis. Today there are no commercial solutions for FPOP
analysis, despite the demonstrated market need for its HOS analytical power.Today's proteomics data analysis products fail to adequately address specific
work-flow, chemical labeling / artifacts, and comparative study requirements of HRPF
HOS analysis. Researchers are compelled to use a piece-meal approach, arduously
stitching together results from multiple packages and manually manipulating data in
home-brew spreadsheets. As such, data processing represents a significant bottleneck
that greatly complicates and delays progress in HRPF HOS studies. Our FoxWare™
software addresses data processing demands of HRPF HOS analysis. Our proposal
vastly improves HRPF data analysis by replacing laborious and agonizing present-day
practices with an integrated, seamless solution to interpret and amplify the value of
HRPF HOS studies. Upon completion of our envisioned program, FoxWare will make an
indelible mark upon HOS analysis and impart a transformative shift in analytics and
HRPF throughput, addressing the market demands of the biopharmaceutical industry.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
12 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $12,046,925. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards